608 related articles for article (PubMed ID: 27745983)
1. Stereotactic Body Radiation Therapy Boost After Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer: A Phase 1 Dose Escalation Study.
Hepel JT; Leonard KL; Safran H; Ng T; Taber A; Khurshid H; Birnbaum A; ; Wazer DE; DiPetrillo T
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1021-1027. PubMed ID: 27745983
[TBL] [Abstract][Full Text] [Related]
2. Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase I Study.
Higgins KA; Pillai RN; Chen Z; Tian S; Zhang C; Patel P; Pakkala S; Shelton J; Force SD; Fernandez FG; Steuer CE; Owonikoko TK; Ramalingam SS; Bradley JD; Curran WJ
J Thorac Oncol; 2017 Nov; 12(11):1687-1695. PubMed ID: 28919394
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study.
Feddock J; Arnold SM; Shelton BJ; Sinha P; Conrad G; Chen L; Rinehart J; McGarry RC
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1325-31. PubMed ID: 23265574
[TBL] [Abstract][Full Text] [Related]
4. Update of a Prospective Study of Stereotactic Body Radiation Therapy for Post-Chemoradiation Residual Disease in Stage II/III Non-Small Cell Lung Cancer.
Kumar S; Feddock J; Li X; Shearer AJ; Hall L; Shelton BJ; Arnold S; McGarry RC
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(3):652-659. PubMed ID: 29280459
[TBL] [Abstract][Full Text] [Related]
5. Precision Hypofractionated Radiation Therapy in Poor Performing Patients With Non-Small Cell Lung Cancer: Phase 1 Dose Escalation Trial.
Westover KD; Loo BW; Gerber DE; Iyengar P; Choy H; Diehn M; Hughes R; Schiller J; Dowell J; Wardak Z; Sher D; Christie A; Xie XJ; Corona I; Sharma A; Wadsworth ME; Timmerman R
Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):72-81. PubMed ID: 26279026
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study.
Jeter MD; Gomez D; Nguyen QN; Komaki R; Zhang X; Zhu X; O'Reilly M; Fossella FV; Xu T; Wei X; Wang H; Yang W; Tsao A; Mohan R; Liao Z
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):730-737. PubMed ID: 29248169
[TBL] [Abstract][Full Text] [Related]
7. Once-weekly, high-dose stereotactic body radiotherapy for lung cancer: 6-year analysis of 60 early-stage, 42 locally advanced, and 7 metastatic lung cancers.
Salazar OM; Sandhu TS; Lattin PB; Chang JH; Lee CK; Groshko GA; Lattin CJ
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):707-15. PubMed ID: 18455322
[TBL] [Abstract][Full Text] [Related]
8. Three-dimensional conformal radiation therapy for non-small-cell lung cancer: a phase I/II dose escalation clinical trial.
Wu KL; Jiang GL; Liao Y; Qian H; Wang LJ; Fu XL; Zhao S
Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1336-44. PubMed ID: 14630271
[TBL] [Abstract][Full Text] [Related]
9. Accelerated Hypofractionated Chemoradiation Followed by Stereotactic Ablative Radiotherapy Boost for Locally Advanced, Unresectable Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
Wu TC; Luterstein E; Neilsen BK; Goldman JW; Garon EB; Lee JM; Felix C; Cao M; Tenn SE; Low DA; Kupelian PA; Steinberg ML; Lee P
JAMA Oncol; 2024 Mar; 10(3):352-359. PubMed ID: 38206614
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer Tumors Greater Than 5 cm: Safety and Efficacy.
Woody NM; Stephans KL; Marwaha G; Djemil T; Videtic GM
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):325-31. PubMed ID: 25841625
[TBL] [Abstract][Full Text] [Related]
11. Definitive chemoradiation therapy following surgical resection or radiosurgery plus whole-brain radiation therapy in non-small cell lung cancer patients with synchronous solitary brain metastasis: a curative approach.
Parlak C; Mertsoylu H; Güler OC; Onal C; Topkan E
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):885-91. PubMed ID: 24495594
[TBL] [Abstract][Full Text] [Related]
12. A Phase I study of chemoradiotherapy with use of involved-field conformal radiotherapy and accelerated hyperfractionation for Stage III non-small cell lung cancer: WJTOG 3305.
Tada T; Chiba Y; Tsujino K; Fukuda H; Nishimura Y; Kokubo M; Negoro S; Kudoh S; Fukuoka M; Nakagawa K; Nakanishi Y
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):327-31. PubMed ID: 22079726
[TBL] [Abstract][Full Text] [Related]
13. Is intermediate radiation dose escalation with concurrent chemotherapy for stage III non-small-cell lung cancer beneficial? A multi-institutional propensity score matched analysis.
Rodrigues G; Oberije C; Senan S; Tsujino K; Wiersma T; Moreno-Jimenez M; Kim TH; Marks LB; Rengan R; De Petris L; Ramella S; DeRuyck K; De Dios NR; Warner A; Bradley JD; Palma DA
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):133-9. PubMed ID: 25835622
[TBL] [Abstract][Full Text] [Related]
14. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
Choi NC; Herndon JE; Rosenman J; Carey RW; Chung CT; Bernard S; Leone L; Seagren S; Green M
J Clin Oncol; 1998 Nov; 16(11):3528-36. PubMed ID: 9817271
[TBL] [Abstract][Full Text] [Related]
15. 30 Gy or 34 Gy? Comparing 2 single-fraction SBRT dose schedules for stage I medically inoperable non-small cell lung cancer.
Videtic GM; Stephans KL; Woody NM; Reddy CA; Zhuang T; Magnelli A; Djemil T
Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):203-8. PubMed ID: 25015198
[TBL] [Abstract][Full Text] [Related]
16. Dose-escalated Hypofractionated Intensity-modulated Radiation Therapy With Concurrent Chemotherapy for Inoperable or Unresectable Non-Small Cell Lung Cancer.
Kim JO; Chu KP; Fairchild A; Ghosh S; Butts C; Chu Q; Gabos Z; Joy AA; Nijjar T; Robinson DM; Sangha R; Scrimger R; Smylie M; Yee D; Roa WH
Am J Clin Oncol; 2017 Jun; 40(3):294-299. PubMed ID: 25333733
[TBL] [Abstract][Full Text] [Related]
17. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.
Bradley J; Graham MV; Winter K; Purdy JA; Komaki R; Roa WH; Ryu JK; Bosch W; Emami B
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):318-28. PubMed ID: 15667949
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
[TBL] [Abstract][Full Text] [Related]
19. The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
Stahl JM; Ross R; Harder EM; Mancini BR; Soulos PR; Finkelstein SE; Shafman TD; Dosoretz AP; Evans SB; Husain ZA; Yu JB; Gross CP; Decker RH
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1011-1020. PubMed ID: 27869080
[TBL] [Abstract][Full Text] [Related]
20. Lung stereotactic body radiation therapy for elderly patients aged ≥ 80 years with pathologically proven early-stage non-small cell lung cancer: a retrospective cohort study.
Watanabe K; Katsui K; Sugiyama S; Yoshio K; Kuroda M; Hiraki T; Kiura K; Maeda Y; Toyooka S; Kanazawa S
Radiat Oncol; 2021 Feb; 16(1):39. PubMed ID: 33622369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
